Horizon Acquires Arthritis Drug | Chemical & Engineering News
Volume 91 Issue 47 | p. 17 | Concentrates
Issue Date: November 25, 2013

Horizon Acquires Arthritis Drug

Department: Business
Keywords: arthritis, royalties, drug marketing

Horizon Pharma will pay $35 million to acquire AstraZeneca’s rights to Vimovo, a delayed-release drug approved to treat osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Vimovo (naproxen/esomeprazole magnesium) can also be used to decrease the risk of gastric ulcers. Under the terms of the agreement, Horizon Pharma will pay 10% royalties to Pozen, AstraZeneca’s partner in developing and marketing the drug.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment